Key result
This review discusses the mechanistic rationale, clinical evidence, and side effect considerations for the six FDA-approved therapies used in the treatment of pulmonary arterial hypertension.
Answers are grounded in this paper and cite their sources.
This review summarizes the diagnostic approach and the mechanistic rationale, evidence, and side effects of six FDA-approved therapies for pulmonary arterial hypertension.
Pulmonary arterial hypertension (PAH) is a progressive disease marked by vasoconstriction and vascular remodeling within pulmonary arteries leading to right heart failure and death. Significant advances in understanding the pathobiology of the disease have identified three key pathways involved in progression of this disease, which are the endothelin pathway, the prostacyclin pathway, and the nitric oxide/cyclic guanosine monophosphate pathway. Echocardiogram is the best screening tool to obtain an estimation of the pulmonary artery systolic pressure but right heart catheterization remains the standard by which the diagnosis is made. There are currently six FDA approved therapies for PAH. The mechanistic rationale, evidence behind their use and side effect considerations in utilizing these therapies in PAH patients will be the focus of this review.
No takes yet. Share an insight, caveat, or question.
Myung H. Park (2008) conducted a review in Pulmonary arterial hypertension (PAH). FDA approved therapies for PAH was evaluated. This review discusses the mechanistic rationale, clinical evidence, and side effect considerations for the six FDA-approved therapies used in the treatment of pulmonary arterial hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: